Analyser av Dignitana

Dignitana Q3’24: Sales in line and better cost control - Redeye

Redeye’s first comments on the Q3 report this morning.

Dignitana: US CMS rates increased for 2025 - Redeye

Redeye comments on the US CMS rate change for 2025.

Dignitana: The way is paved for standard of care - Redeye

Redeye comments on the announcement of a significant milestone: the AMA issues permanent CPT® Category I codes for scalp cooling, set to tak...

Redeye • 21 Oct 07:28

Dignitana Q2’24: Lowering expectations - Redeye

Redeye’s long-term view of Dignitana is, to a degree, intact, even if the sales progression has been a disappointment.

Redeye • 23 Aug 09:09

Dignitana Q2’24: A bit lackluster - Redeye

Redeye’s first comments on the Q2 report this morning.

Redeye • 22 Aug 09:19

Dignitana: Sales coming in flat - Redeye

Redeyes’ long-term view of Dignitana is intact despite the flat sales progression.

Redeye • 24 May 07:36

Dignitana Q1’24: Slightly weaker sales but solid gross margin - Redeye

Redeye's first comments on the Q1 report this morning.

Redeye • 23 May 09:49

Dignitana: Positive steps in the Japanese market - Redeye

Redeye comments on the new multi-year agreement that Dignitana has signed with Konica Minolta in Japan.

Redeye • 22 May 09:03

Dignitana: Change at the helm - Redeye

Redeye comments on the change of CEO.

Redeye • 25 Apr 09:38

Dignitana: Rights issue concluded - Redeye

Redeye adjusts the Fair value range and Base case after the outcome of the rights issue has been concluded.

Redeye • 04 Apr 15:49

Dignitana: Secured rights issue announced - Redeye

Redeye comments on last night’s news about a 92.3% secured rights issue of SEK19.

Redeye • 22 Feb 12:32

Dignitana Q4’23: Growing and a positive EBITDA - Redeye

Redeye's first comments on the Q4 report this morning.

Redeye • 15 Feb 08:42

Dignitana: Delta approval in Japan a positive signal - Redeye

Redeye comments that Dignitana has received market approval for DigniCap Delta in Japan.

Redeye • 13 Feb 09:24

Dignitana: Strong preliminary results from study - Redeye

Redeye comments on the preliminary results of the DignCap Delta study in Uruguay, stating that the first phase demonstrated a 79% success ra...

Redeye • 17 Jan 08:58

Dignitana: New agreement for distribution in Switzerland - Redeye

Redeye is favorable to the expansion of the distribution network for Switzerland and Lichtenstein by Dignitana.

Redeye • 16 Jan 10:11

Dignitana: Keep your eyes on the prize - Redeye

Redeyes’ long-term view of Dignitana is intact. The sales progression was softer than we expected.

Redeye • 17 Nov 2023 07:17

Dignitana Q3’23: Slightly softer top line with a positive EBITDA - Redeye

Redeye's first comments on the Q3 report this morning.

Redeye • 16 Nov 2023 09:13

Dignitana: Somewhat dissapointing news – but not a significant conern in practice - Redeye

Redeye comments on the decision by CMS to decrease the average rate for 2024 under the Hospital Outpatient Prospective Payment System and Am...

Redeye • 07 Nov 2023 15:43

Dignitana: Sales and marketing partnership to push sales in the US - Redeye

Redeye comments on the news that Dignitana has entered into a sales and marketing partnership with Infusystems Holdings Inc.

Redeye • 04 Oct 2023 09:57

Dignitana: The first LCD is approved in the US - Redeye

Redeye comments on the news that the first Medicare Administrative Contractor (MAC) has approved the proposed Local Coverage Determination (...

Redeye • 03 Oct 2023 13:50

Dignitana Q2’23: Still on the trajectory - Redeye

Redeyes’ view on Dignitana is generally unchanged. The sales momentum continued even if it was slightly lower than our expectations.

Redeye • 18 Aug 2023 07:57

Dignitana Q2’23: First impression – slightly softer than expected - Redeye

Redeye's first comments on the Q2 report this morning.

Redeye • 17 Aug 2023 09:28

Dignitana: Positive signals for US reimbursement process - Redeye

Redeye comments on the news that a Medicare Administrative Contractor (MAC) has issued a proposed Local Coverage Determination (LCD) in the ...

Redeye • 15 Jun 2023 12:15

Dignitana Q1’23: Reaching the inflection point - Redeye

Redeyes’ view on Dignitana is generally unchanged. The sales momentum continued in the quarter with better cost control.

Redeye • 26 May 2023 07:31

Dignitana Q1’23: First impression – positive EBITDA - Redeye

Redeye's first comments on the Q1 report this morning.

Redeye • 25 May 2023 08:57

Dignitana Q4’22: First impression – weaker gross margin - Redeye

Redeye's first comments on the Q4 report this morning.

Redeye • 16 Feb 2023 10:42

Dignitana Q3’22: Positive signs from the most important market - Redeye

Redeye is impressed with how Dignitana continues to drive growth.

Redeye • 18 Nov 2022 07:32

Dignitana Q3’22: First impression – on the right track - Redeye

Redeye's first comments on the Q3 report this morning.

Redeye • 17 Nov 2022 09:01

Dignitana: Direct share issue to drive growth - Redeye

Redeye is positive to the news of a direct share issue done yesterday that will bring SEK 25m before costs.

Redeye • 19 Oct 2022 09:22

Dignitana Q2: EBIT turns positive in the quarter - Redeye

Redeye comments on Dignitana’s Q2 report. Sales continue to develop well, even if we had hoped for even stronger growth than the 30% that th...

Redeye • 19 Aug 2022 07:42

Dignitana Q2: First take – Positive EBIT - Redeye

Redeye's first comments on the Q2 report this morning.

Redeye • 18 Aug 2022 09:19

Dignitana: Positive momentum Continues - Redeye

Redeye comments on Dignitana’s Q1 report. The positive sales trend from the end of 2021 continues into 2022.

Redeye • 20 May 2022 10:09

Dignitana: Initial comments - Redeye

Redeye’s first comments on the Q1 report released earlier this morning that showed continued good growth and an impressive increase in the A...

Redeye • 19 May 2022 11:23

Dignitana Q4’21: Strong finish to an eventful year - Redeye

Redeye continues to see a compelling case that has laid a good foundation for growth in 2022.

Redeye • 18 Feb 2022 12:26

Dignitana Q4’21: Initial comments - Redeye

Redeye’s first comments on the Q4 report this morning.

Redeye • 17 Feb 2022 09:32

Dignitana: Q2’21: Signals of better times ahead - Redeye

Redeye comments on Dignitana's Q2 report. The sales development continues to be positive in uncertain markets.

Redeye • 20 Aug 2021 10:31

Dignitana Q2’21: Initial take - Redeye

Redeye first comments on Dignitana's Q2 report. The sales development continues to be strong with a 23 % growth in the quarter which was alm...

Redeye • 19 Aug 2021 13:22

Börskollen

För dig med koll på börsen